Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
devdiscourse21h
Health Sector Headlines: High-Stakes Decisions and Market Moves
Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...
Opening Day: Infinity Natural Resources valued at $1.3B in market debut
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...